Immunai joins 10x Genomics program to boost drug development
Together, the two companies say can give drugmakers a better view at the cellular level of how a patient’s immune system is responding to a cerain therapy.
Together, the two companies say can give drugmakers a better view at the cellular level of how a patient’s immune system is responding to a cerain therapy.
The company, led by an ex-Palantir engineer and a former Harvard postdoctoral researcher, has developed machine learning algorithms to identify nuances in cells, mechanisms of action and biomarkers that could aid immunotherapy and cell therapy development.